• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Psoriasis Drug Skyrizi is Now Available as a Single Injection

News
Article

Previously patients administered as two, 75-mg shots. Now they can inject a single 150-mg dose.

AbbVie’s Skyrizi (risankizumab-rzaa) is now available in the United States as a single-dose 150 mg injection for the treatment of adults with moderate-to-severe plaque psoriasis. Previously two 75-mg injections per dose, the 150 mg dosage is now administered with one injection per dose either with a prefilled pen or syringe every 12 weeks following two starter doses.

The new Skyrizi 150-mg pen incorporates wide grip handles, audible cues to help guide the administration process, and an indicator to signal when administration is complete.

The FDA approved Skyrizi 150 mg in April based on data from three clinical trials showing the single-dose 150 mg injection was bioequivalent to two injections of 75 mg per dose each.

“We know many people living with psoriasis are looking for flexibility in how they manage their disease,” Patrick Horber, president, U.S. Immunology at AbbVie, said in a statement. “That's why we're proud to provide an updated Skyrizi treatment experience that allows for fewer injections of the same Skyrizi that patients and providers have come to know and trust.”

Skyrizi is part of a collaboration between AbbVie and Boehringer Ingelheim.

Psoriasis affects more than 3% of the U.S. adult population, or about 7.5 million people.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.